Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GK02
- Development stage
- Phase 1
- Lead developer
- Beijing Geek Gene Technology
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GK02 is an autologous tumor-reactive T-cell therapy developed by Beijing Geekgene Technology Co., LTD for the treatment of malignant ascites associated with advanced solid tumors. The therapy is produced by isolating T cells from a patient's own malignant ascites fluid, which are naturally primed to recognize tumor-associated antigens within the peritoneal environment. These cells are expanded ex vivo to therapeutic quantities and then re-infused into the patient. By leveraging the natural tumor-homing and recognition capabilities of T cells found within the malignant fluid, GK02 aims to provide a targeted immune response to eliminate cancer cells and reduce the accumulation of malignant ascites, offering a potential improvement over conventional palliative treatments.
- Other names
- autologous tumor-reactive T cells
02
Targets
EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on GK02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GK02.